Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis illuminates drug positioning through primary market research-based insights from physicians and DRG oncology experts’ assumptions.
Treatment Sequencing 2017 covers six oncology indications with competitive treatment landscapes:
- Renal cell carcinoma (US)
- Malignant melanoma (US)
- Non-small-cell lung cancer (US)
- Breast cancer (US)
- Prostate cancer (EU5)
- Chronic myeloid leukemia (US)